JPH09501433A - 抗−分裂剤としてのエストロゲン性化合物 - Google Patents
抗−分裂剤としてのエストロゲン性化合物Info
- Publication number
- JPH09501433A JPH09501433A JP7506502A JP50650295A JPH09501433A JP H09501433 A JPH09501433 A JP H09501433A JP 7506502 A JP7506502 A JP 7506502A JP 50650295 A JP50650295 A JP 50650295A JP H09501433 A JPH09501433 A JP H09501433A
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- ocor
- independently
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.製薬学的に許容し得る担体中に、式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Re、Rf、Ri、Rj、Rk、Rl、Rm、Roは各々独 立して−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br又は −Iであり;Rgは−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、 −Br、−I又は−C≡CHである、 又は B)Ra、Rb、Rc、Rf、Rk、Rl、Roは各々独立して−R1、−OR1、− OCOR1、−SR1、−F、−NHR2、−Br又は−Iであり;Rd、Re、Ri 、Rj、Rmは各々独立して=O、−R1、−OR1、−OCOR1、−SR1、−F 、−NHR2、−Br又は−Iであり;Rgは=O、−R1、−OR1、−OCOR1 、−SR1、−F、−NHR2、−Br、−I又は−C≡CHである、 そして II.Z’は以下の通りに定義され: A)Z’はXであり、ここでXは>COR1、 である、 又は −OR1、−SR1、−F、−NHR2、−Br又は−Iであり;X’は上記で定 義されたXであるか;又はX’は>C=Oである; そして III.Z”は以下の通りに定義され: であり、ここでnは0〜6である; 又は −OR1、−SR1、−F、−NHR2、−Br又は−Iである; そして IV.但し、Rb、Rc、Rd、Re、Ri、Rj、Rk、Rl、Rm及びRoが各々Hで あり; Rfが−CH3であり; Rgが−OHであり; Z’が>COHであり; Z”が>CH2である場合、 Raは−Hではなく; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物を含む、異常な細胞有糸分裂を阻害することができ る薬剤の製造法。 2.製薬学的に許容し得る担体中に、式: [式中: I.Ra−Rkは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Rg、Rh、Ri、Rkは各々独立して−R1、−OR1 、−OCOR1、−SR1、−F、−NHR2、−Br又は−Iであり;Reは−R1 、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br、−I又は−C ≡CHである、 又は B)Ra、Rb、Rc、Rd、Rkは各々独立して−R1、−OR1、−OCOR1、 −SR1、−F、−NHR2、−Br又は−Iであり;Rg、Rh、Riは各々独立 して=O、−R1、−OR1、−OCOR1、−SR1、−F、−Br又は−Iであ り;Reは=O、−R1、−OR1、−OCOR1、−SR1、−F、−Br、−I 又は−C≡CHである、 そして II.Z’は以下の通りに定義され: A)Z’はXであり、ここでXは>COR1、 である、 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; X’は上記で定義されたXであるか;又はX’も>C=Oである; そして III.Z”は以下の通りに定義され: であり、ここでnは0〜6である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物を含む、異常な細胞有糸分裂を阻害することができ る薬剤の製造法。 3.製薬学的に許容し得る担体中に、式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Re、Rf、Ri、Rj、Rk、Rl、Rm、Roは各々独 立して−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br又は −Iであり;Rgは−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、 −Br、−I又は−C≡CHである、 又は B)Ra、Rb、Rc、Rf、Rk、Rlは各々独立して−R1、−OR1、−OCO R1、−SR1、−F、−NHR2、−Br又は−Iであり;Rd、Re、Ri、Rj 、Rm、Roは各々独立して=O、−R1、−OR1、−OCOR1、−SR1、−F 、−NHR2、−Br又は−Iであり;Rgは=O、−R1、−OR1、−OCOR1 、−SR1、−F、−NHR2、−Br、−I又は−C≡CHである、 そして II.Zは以下の通りに定義され: であり、ここでnは0〜6である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物を含む、異常な細胞有糸分裂を阻害することができ る薬剤の製造法。 4.製薬学的に許容し得る担体中に、式: [式中: I.Ra−Rkは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Rg、Rh、Ri、Rkは各々独立して−R1、−OR1 、−OCOR1、−SR1、−F、−NHR1、−Br又は−Iであり;Reは−R1 、−OR1、−OCOR1、−SR1、−F、−NHR1、−Br、−I又は−C ≡CHである、 又は B)Ra、Rb、Rc、Rdは各々独立して−R1、−OR1、−OCOR1、−S R1、−F、−NHR1、−Br又は−Iであり;Rg、Rh、Ri、Rkは各々独立 して=O、−R1、−OR1、−OCOR1、−SR1、−F、−NHR1、−Br 又は−Iであり;Reは=O、−R1、−OR1、−OCOR1、−SR1、−F、 −NHR1、−Br、−I又は−C≡CHである、 そして II.Zは以下の通りに定義され: であり、ここでnは0〜6である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物を含む、異常な細胞有糸分裂を阻害することができ る薬剤の製造法。 5.製薬学的に許容し得る担体中に、式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Re、Rf、Rg、Rh、Rj、Rk、Rl、Rm、Rn、 Roは各々独立して−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、 −Br又は−Iであり;Riは−R1、−OR1、−OCOR1、−SR1、−F、 −NHR2、−Br、−I又は−C≡CHである、 又は B)Ra、Rd、Rf、Rj、Rm、Rn、Roは各々独立して−R1、−OR1、− OCR1、−SR1、−F、−NHR2、−Br又は−Iであり;Rb、Rc、Re、 Rg、Rh、Rk、Rlは各々独立して=O、−R1、−OR1、−OCOR1、−S R1、−F、−NHR1、−Br又は−Iであり;Riは=O、−R1、−OR1、 −OCOR1、−SR1、−F、−Br、−I又は−C≡CHである、 又は C)Ra、Rb、Rc、Rd、Rf、Rj、Rm、Rn、Roは各々独立して−R1、− OR1、OCR1、−SR1、−F、−NHR2、−Br、−Iであり、Re、Rg、 Rh、Rk、Rlは各々独立して=O、−R1、−OR1、−OCOR1、−SR1、 −F,−NHR1、−Br又は−Iであり;Riは=O、−R1、−OR1、−OC OR1、−SR1、−F、−Br、−I又は−C≡CHであり; II.Zは以下の通りに定義され: A)ZはXであり、ここでXは >COR1, である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; X’は上記で定義されるXであるか、又はX’は>C=Oであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で あり;C…Cにより示される結合は不在であるか、又はC−C結合と組み合わさ れて、単位HC=CHである] の細胞有糸分裂−阻害化合物を含む、異常な細胞有糸分裂を阻害することができ る薬剤の製造法。 6.製薬学的に許容し得る担体中に、式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Re、Rg、Rh、Rk、Rl、Rm、Rn、Roは各々独立し て−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br又は−I であり;Riは−R1、−OR1、−OCOR1、−SR1、 −F、−NHR2、−Br、−I又は−C≡CHである、 又は B)Ra、Re、Rl、Rm、Rn、Roは各々独立して−R1、−OR1、−OCO R1、−SR1、−F、−NHR2、−Br、−Iであり;Rb、Rc、Rg、Rhは 各々=O、−R1、−OR1、−OCOR1、−SR1、一F、−NHR1、−Br 又は−Iであり;Riは=O、−R1、−OR1、−OCOR1、−SR1、−F、 −NHR1、−Br、−I又は−C≡CHである、 又は C)Ra、Rb、Rc、Re、Rk、Rm、Rn、Roは各々独立して−R1、−OR1 、−OCOR1、−SR1、−F、−NHR2、−Br、−Iであり、Rh、Riは 各々独立して=O、−R1、−OR1、−OCOR1、−SR1、−F、−NHR1 、−Br又は−Iであり;Riは=O、−R1、−OR1、−OCOR1、−SR1 、−F、−NHR1、−Br、−I又は−C≡CHであり; I.Zは以下の通りに定義され: A)ZはXであり、ここでXは >COR1, である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; X’は上記で定義されるXであるか、又はX’は=Oであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で あり;C…Cにより示される結合は不在であるか、又はC−C結合と組み合わさ れて、単位HC=CHである] の細胞有糸分裂−阻害化合物を含む、異常な細胞有糸分裂を阻害することができ る薬剤の製造法。 7.一般式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Re、Rf、Ri、Rj、Rk、Rl、Rm、Roは各々独 立して−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br又は −Iであり;Rgは−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、 −Br、−I又は−C≡CHである、 又は B)Ra、Rb、Rc、Rf、Rk、Rl、Roは各々独立して−R1、−OR1、− OCOR1、−SR1、−F、−NHR2、−Br又は−Iであり;Rd、Re、Ri 、Rj、Rmは各々独立して=O、−R1、−OR1、− OCOR1、−SR1、−F、−NHR2、−Br又は−Iであり;Rgは=O、− R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br、−I又は− C≡CHである、 そして II.Z’は以下の通りに定義され: A)Z’はXであり、ここでXは>COR1、 である、 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであるか;又はX ’は上記で定義されたXであるか;又はX’は>C=Oである; そして III.Z”は以下の通りに定義され: であり、ここでnは0〜6である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; 但し 3)Rb、Rc、Rd、Re、Rj、Rk、Rl、Rmが各々Hであり; Rfが−CH3であり; Riが−H、−OH又は=Oであり; Roが−H又は−Brであり; Z’が>COHであり; Z”が>CH2又は−OHである場合、 Raは−F、−Br、−OH又は−Hではなく; そして 4)Rb、Rc、Rd、Re、Ri、Rj、Rk、Rl、Rmが各々−Hであり; Rfが−CH3であり; Rgが−OHであり; Z”が>CH2である場合、 Ra、Roは各々独立して又は一緒に−OCH3又は−Hではなく; そして 5)Rc、Re、Ri、Rk、Rl、Rm、Roが各々−Hであり; Raが−H又は−OCH3であり; Rbが−H又は−CH3であり; Rdが−OHであり; Rfが−CH3であり; Rgが=Oであり; Riが−OH、=O又は−C≡CHであり; Z”が>CH2である場合、 ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物である化合物。 8.一般式: [式中: I.Ra−Rkは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Rg、Rh、Ri、Rkは各々独立して−R1、−OR1 、−OCOR1、−SR1、−F、−NHR2、−Br又は−Iであり;Reは−R1 、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br、−I又は−C ≡CHである、 又は B)Ra、Rb、Rc、Rd、Rkは各々−R1、−OR1、−OCOR1、−SR1 、−F、−NHR2、−Br又は−Iであり;Rg、Rh、Riは各々独立して=O 、−R1、−OR1、−OCOR1、−SR1、−F、−Br又は−Iであり;Re は=O、−R1、−OR1、−OCOR1、−S R1、−F、−Br、−I又は−C≡CHである、 そして I.Z’は以下の通りに定義され: A)Z’はXであり、ここでXは>COR1、 である、 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; X’は上記で定義されたXであるか;又はX’も>C=Oである; そして II.Z”は以下の通りに定義され: であり、ここでnは0〜6である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物である化合物。 9.一般式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Re、Rf、Ri、Rj、Rk、Rl、Rm、Roは各々独 立して−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br又は −Iであり;Rgは−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、 −Br、−I又は−C≡CHである、 又は B)Ra、Rb、Rc、Rf、Rk、Rlは各々独立して−R1、−OR1、−OCO R1、−SR1、−F、−NHR2、−Br又は−Iであり;Rd、Re、Ri、Rj 、Rm、Roは各々独立して=O、−R1、−OR1、−OCOR1、−SR1、−F 、−NHR2、−Br又は−Iであり;Rgは=O、−R1、−OR1、−OCOR1 、−SR1、−F、−NHR2、−Br、−I又は−C≡CHである、 そして II.Zは以下の通りに定義され: であり、ここでnは0〜6である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物である化合物。 10.一般式: [式中: I.Ra−Rkは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Rg、Rh、Ri、Rkは各々独立して−R1、−OR1 、−OCOR1、−SR1、−F、−NHR1、−Br又は−Iであり;Reは−R1 、−OR1、−OCOR1、−SR1、−F、−NHR1、−Br、−I又は−C ≡CHである、 又は B)Ra、Rb、Rc、Rdは各々独立して−R1、−OR1、−OCOR1、−S R1、−F、−NHR1、−Br又は−Iであり;Rg、Rh、Ri、Rkは各々独立 して=O、−R1、−OR1、−OCOR1、−SR1、−F、−NHR1、−Br 又は−Iであり;Reは−R1、−OR1、−OCOR1、−SR1、−F、−NH R1、−Br、−I又は−C≡CHであ る、 II.Zは以下の通りに定義され: であり、ここでnは0〜6である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で ある] の細胞有糸分裂−阻害化合物である化合物。 11.一般式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Rd、Re、Rf、Rg、Rh、Rj、Rk、Rl、Rm、Rn、 Roは各々独立して−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、 −Br又は−Iであり;Riは−R1、−OR1、−OCOR1、−SR1、−F、 −NHR2、−Br、−I又は−C≡CHである、 又は B)Ra、Rd、Rf、Rj、Rm、Rn、Roは各々独立して−R1、−O R1、−OCR1、−SR1、−F、−NHR2、−Br、−Iであり;Rb、Rc、 Re、Rg、Rh、Rk、Rlは各々独立して=O、−R1、−OR1、−OCOR1、 −SR1、−F、−NHR1、−Br又は−Iであり;Riは=O、−R1、−OR1 、−OCOR1、−SR1、−F、−NHR1、−Br、−I又は−C≡CHであ る、 又は C)Ra、Rb、Rc、Rd、Rf、Rj、Rm、Rn、Roは各々独立して−R1、− OR1、OCR1、−SR1、−F、−NHR2、−Br、−Iであり、Re、Rg、 Rh、Rk、Rlは各々独立して=O、−R1、−OR1、−OCOR1、−SR1、 −F、−NHR1、−Br又は−Iであり;Riは=O、−R1、−OR1、−OC OR1、−SR1、−F、−NHR1、−Br、−I又は−C≡CHであり; I.Zは以下の通りに定義され: A)ZはXであり、ここでXは >COR1, である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; X’は上記で定義されるXであるか、又はX’は>C=Oであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又 はアルキニル基であり;C…Cにより示される結合は不在であるか、又はC−C 結合と組み合わされて、単位HC=CHである] の細胞有糸分裂−阻害化合物である化合物。 12.一般式: [式中: I.Ra−Roは以下の通りに定義され: A)Ra、Rb、Rc、Re、Rg、Rh、Rk、Rl、Rm、Rn、Roは各々独立し て−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−Br又は−I であり;Riは−R1、−OR1、−OCOR1、−SR1、−F、−NHR2、−B r、−I又は−C≡CHである、 又は B)Ra、Re、Rl、Rm、Rn、Roは各々独立して−R1、−OR1、−OCO R1、−SR1、−F、−NHR2、−Br、−Iであり;Rb、Rc、Rg、Rhは 各々=O、−R1、−OR1、−OCOR1、−SR1、−F、−NHR1、−Br 又は−Iであり;Riは=O、−R1、−OR1、−OCOR1、−SR1、−F、 −NHR1、−Br、−I又は−C≡CHである、 又は C)Ra、Rb、Rc、Re、Rk、Rm、Rn、Roは各々独立して−R1、−OR1 、−OCOR1、−SR1、−F、−NHR2、−Br、−Iであり、Rg、Rhは 各々独立して=O、−R1、−OR1、−OCOR1、−SR1、−F、−NHR1 、−Br又は−Iであり;Riは=O、−R1、−OR1、−OCOR1、−SR1 、−F、−NHR1、−Br、−I又は−C≡CHであり; II.Zは以下の通りに定義され: A)ZはXであり、ここでXは >COR1, である; 又は −R1、−OR1、−SR1、−F、−NHR2、−Br又は−Iであり; X’は上記で定義されるXであるか、又はX’は=Oであり; ここで上記に示した各式において、R1及びR2は各々独立して−H、あるいは炭 素数が1〜6の置換もしくは非置換のアルキル、アルケニル又はアルキニル基で あり;C…Cにより示される結合は不在であるか、又はC−C結合と組み合わさ れて、単位HC=CHである] の細胞有糸分裂−阻害化合物である化合物。 13.該細胞有糸分裂−阻害化合物が2−メトキシエストラジオールである請 求の範囲第1項の方法。 14.該細胞有糸分裂−阻害化合物が2−フルオロエストラジオール である請求の範囲第1項の方法。 15.該細胞有糸分裂−阻害化合物が2−ブロモエストラジオールである請求 の範囲第1項の方法。 16.該細胞有糸分裂−阻害化合物が2−メトキシエストロンである請求の範 囲第1項の方法。 17.該有糸分裂−阻害化合物が17−エチニルエストラジオールである請求 の範囲第1項の方法。 18.該化合物がさらに ことを特徴とする請求の範囲第1又は2項の方法。 であることを特徴とする請求の範囲第3又は4項の方法。 であることを特徴とする請求の範囲第5又は6項の方法。 21.該化合物がさらに ことを特徴とする請求の範囲第7又は8項に記載の化合物。 であることを特徴とする請求の範囲第9又は10項の化合物。 であることを特徴とする請求の範囲第11又は12項の化合物。 24.Ra−Rpの少なくとも1つが−OCH3である請求の範囲第1〜6項の いずれか1つに記載の方法。 25.Ra−Rpの少なくとも1つが−OCH3である請求の範囲第7〜12項 のいずれか1つに記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/102,767 US5504074A (en) | 1993-08-06 | 1993-08-06 | Estrogenic compounds as anti-angiogenic agents |
US08/102,767 | 1993-08-06 | ||
PCT/US1994/008767 WO1995004535A1 (en) | 1993-08-06 | 1994-08-02 | Estrogenic compounds as anti-mitotic agents |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008041711A Division JP2008120840A (ja) | 1993-08-06 | 2008-02-22 | 抗−分裂剤としてのエストロゲン性化合物 |
JP2008041709A Division JP2008120839A (ja) | 1993-08-06 | 2008-02-22 | 抗−分裂剤としてのエストロゲン性化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09501433A true JPH09501433A (ja) | 1997-02-10 |
Family
ID=22291581
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7506502A Ceased JPH09501433A (ja) | 1993-08-06 | 1994-08-02 | 抗−分裂剤としてのエストロゲン性化合物 |
JP2008041709A Pending JP2008120839A (ja) | 1993-08-06 | 2008-02-22 | 抗−分裂剤としてのエストロゲン性化合物 |
JP2008041711A Pending JP2008120840A (ja) | 1993-08-06 | 2008-02-22 | 抗−分裂剤としてのエストロゲン性化合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008041709A Pending JP2008120839A (ja) | 1993-08-06 | 2008-02-22 | 抗−分裂剤としてのエストロゲン性化合物 |
JP2008041711A Pending JP2008120840A (ja) | 1993-08-06 | 2008-02-22 | 抗−分裂剤としてのエストロゲン性化合物 |
Country Status (12)
Country | Link |
---|---|
US (8) | US5504074A (ja) |
EP (3) | EP1640009B1 (ja) |
JP (3) | JPH09501433A (ja) |
AT (2) | ATE313327T1 (ja) |
AU (1) | AU7450994A (ja) |
CA (1) | CA2168850C (ja) |
DE (2) | DE69434584T2 (ja) |
DK (2) | DK0713393T3 (ja) |
ES (2) | ES2315763T3 (ja) |
HK (2) | HK1014504A1 (ja) |
PT (1) | PT1640009E (ja) |
WO (1) | WO1995004535A1 (ja) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6908910B2 (en) * | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
US20040214807A1 (en) * | 1993-08-06 | 2004-10-28 | D'amato Robert J. | Estrogenic compounds as anti-mitotic agents |
US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
WO1996040150A1 (en) * | 1995-06-07 | 1996-12-19 | Merck & Co., Inc. | Treatment and prevention of prostatic disease |
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US20030195180A1 (en) * | 1995-12-12 | 2003-10-16 | D'amato Robert John | Estrogenic compounds as anti-mitotic agents |
ATE281170T1 (de) | 1996-05-09 | 2004-11-15 | Amrad Operations Pty Ltd | Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen |
JP2000515523A (ja) * | 1996-07-22 | 2000-11-21 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用 |
US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
US5801012A (en) | 1996-09-17 | 1998-09-01 | Northwestern University | Methods and compositions for generating angiostatin |
DE19654750A1 (de) * | 1996-12-30 | 1998-07-02 | Helmut Dr Med Zander | Verwendung von Wirkstoffen mit Östrogen-Wirkung zur Vorbeugung und Behandlung von Makuladegeneration |
WO1998040077A1 (en) * | 1997-03-11 | 1998-09-17 | Allergan Sales, Inc. | Anti-angiogenic agents |
WO1998042328A1 (en) | 1997-03-26 | 1998-10-01 | Biosource Technologies, Inc. | Di-aryl ethers and their derivatives as anti-cancer agents |
WO1998056372A1 (en) | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
US20020002294A1 (en) * | 1997-09-24 | 2002-01-03 | D' Amato Robert J. | Estrogenic compounds as antiangiogenic agents |
US6355630B1 (en) | 1997-10-23 | 2002-03-12 | American Home Products Corporation | Estra-1,3,5(10)-triene-7α-thioethers |
US6689768B2 (en) * | 1998-04-15 | 2004-02-10 | Jenapharm Gmbh & Co. Kg | Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy |
EP2311490A3 (en) | 1998-07-13 | 2011-05-04 | Board of Regents, The University of Texas System | Uses of antibodies to aminophospholipids for cancer treatment |
WO2000007576A2 (en) * | 1998-08-07 | 2000-02-17 | Endorecherche, Inc. | INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE |
ATE284682T1 (de) | 1998-08-11 | 2005-01-15 | Entremed Inc | Verwendung von 2-methoxyestradiol als fungizide |
EP1234585A3 (en) | 1998-09-04 | 2004-01-21 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
AU3579200A (en) * | 1999-02-26 | 2000-09-14 | Saltech I Goteborg Ab | Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1 |
CA2376297A1 (en) * | 1999-08-23 | 2001-03-01 | Gregory E. Agoston | Methods of obtaining 2-methoxyestradiol of high purity |
US7087592B1 (en) * | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
PT1955700E (pt) | 1999-09-30 | 2011-05-04 | Harbor Biosciences Inc | Tratamento terap?utico de doen?as associadas ao receptor de androg?nios |
AUPQ342599A0 (en) | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
US6696436B1 (en) | 1999-10-26 | 2004-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | B-homoestra-1,3,5(10)-trienes as modulators of tubulin polymerization |
US6518261B2 (en) * | 2000-03-17 | 2003-02-11 | Oncology Sciences Corporation | Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers |
US7135581B2 (en) | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
US20050192258A1 (en) * | 2000-08-18 | 2005-09-01 | Agoston Gregory E. | Antiangiogenic agents |
US6995278B2 (en) * | 2000-08-18 | 2006-02-07 | Entre Med, Inc. | Antiangiogenic agents |
WO2002042319A2 (en) * | 2000-11-27 | 2002-05-30 | Entremed, Inc. | 2-substituted estrogens as antiangiogenic agents |
US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
US7037906B1 (en) * | 2000-12-22 | 2006-05-02 | Oxigene, Inc. | Methods for modulating tumor growth and metastasis |
US6632835B2 (en) | 2001-02-22 | 2003-10-14 | Nanodesign Inc. | Dibenzo[c]chromen-6-one derivatives as anti-cancer agents |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US6593321B2 (en) | 2001-06-11 | 2003-07-15 | Southwest Foundation For Biomedical Research | 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
JP2004536847A (ja) * | 2001-07-13 | 2004-12-09 | オキシジーン, インコーポレイテッド | 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 |
US20040229960A1 (en) * | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
US7488723B2 (en) * | 2001-09-05 | 2009-02-10 | Alcon, Inc. | Use of non-feminizing estrogens as treatment for retinal vascular diseases |
US20030139374A1 (en) * | 2001-09-27 | 2003-07-24 | Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. | Combined methods for tumor vasculature coagulation and treatment |
US20080279936A1 (en) * | 2001-10-10 | 2008-11-13 | The University Of Pittsburgh | Estradiol metabolites for reduction of endothelin production |
US7023931B2 (en) * | 2001-11-05 | 2006-04-04 | Texas Instruments Incorporated | System and method for soft slicing |
US7179798B2 (en) * | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
AU2003209439A1 (en) * | 2002-01-30 | 2003-09-02 | Entremed, Inc. | Non-steroidal analogs of 2-methoxyestradiol |
WO2003073985A2 (en) * | 2002-03-01 | 2003-09-12 | Entremed, Inc. | New methods of using antiangiogenic agents |
WO2004037164A2 (en) * | 2002-06-21 | 2004-05-06 | University Of Utah Research Foundation | Crosslinked compounds and methods of making and using thereof |
CA2491310C (en) | 2002-07-15 | 2015-10-06 | Board Of Regents, The University Of Texas System | Compositions comprising cell-impermeant duramycin derivatives |
US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
JP2006525030A (ja) | 2003-05-07 | 2006-11-09 | セダーズ−シナイ メディカル センター | 細胞内エストラジオール結合タンパク質、このタンパク質をコードするポリヌクレオチドおよびこのタンパク質を過剰発現する細胞 |
CA2525788A1 (en) | 2003-05-15 | 2005-01-06 | University Of Utah Research Foundation | Anti-adhesion composites and methods of use thereof |
US7371741B2 (en) * | 2003-05-28 | 2008-05-13 | Entremed, Inc. | Estradiol derivatives and pharmaceutical compositions using same |
US20050032766A1 (en) * | 2003-08-05 | 2005-02-10 | Green Shawn J. | Use of estrogenic compounds as anti-fungal agents |
US20050065136A1 (en) * | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
WO2005051357A1 (en) * | 2003-11-19 | 2005-06-09 | Entremed, Inc. | Antiangiogenic agents |
US20100330143A1 (en) | 2003-12-04 | 2010-12-30 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
ZA200604869B (en) * | 2003-12-04 | 2007-11-28 | Univ Utah Res Found | Modified macromolecules and methods of making and using thereof |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
CN102258503B (zh) | 2004-01-22 | 2019-08-16 | 迈阿密大学 | 局部辅酶q10制剂及其使用方法 |
US20070004689A1 (en) * | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
JP2007529426A (ja) * | 2004-03-12 | 2007-10-25 | エントレメッド インコーポレイテッド | 抗血管新生薬 |
WO2005105107A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of multiple sclerosis |
WO2005105106A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of macular degeneration |
US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US20050244465A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
WO2005110462A2 (en) | 2004-05-04 | 2005-11-24 | Children's Medical Center Corporation | Methods and compositions for treatment of preeclampsia |
EP1773350B1 (en) * | 2004-07-12 | 2013-05-29 | Allergan, Inc. | Opthalmic compositions for treating ophthalmic conditions |
US20060025390A1 (en) * | 2004-07-28 | 2006-02-02 | Roby Russell R | Treatment of hormone allergy and related symptoms and disorders |
TW200611909A (en) * | 2004-08-04 | 2006-04-16 | Akzo Nobel Nv | Process for the preparation 2-substituted-derivatives of estrone and estradiol |
TW200613316A (en) * | 2004-08-26 | 2006-05-01 | Akzo Nobel Nv | Process for the preparation of estrone and/or estradiol-derivates |
MX2007003522A (es) | 2004-09-24 | 2007-06-11 | Beth Israel Hospital | Complicaciones del embarazo. |
WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
AU2005309455A1 (en) * | 2004-11-29 | 2006-06-01 | Entremed, Inc. | A method of administering anti-angiogenic agents and a method of treating disease using same |
US20060148674A1 (en) * | 2004-12-31 | 2006-07-06 | Luduena Richard F | Therapeutic composition |
US8168621B2 (en) * | 2005-09-30 | 2012-05-01 | Endece, Llc | 6-substituted estradiol derivatives and methods of use |
US20080119447A1 (en) * | 2005-09-30 | 2008-05-22 | James Yarger | 6-alkoxyalkyl estradiol derivatives and methods of use |
US10174070B2 (en) * | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
WO2007059111A2 (en) * | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
US7627508B2 (en) * | 2006-01-04 | 2009-12-01 | S.R. Clarke, Inc. | Method for tracking employees |
US20070176403A1 (en) * | 2006-02-01 | 2007-08-02 | Dennis Calderone | Air adjustable seat |
US20070203227A1 (en) * | 2006-02-24 | 2007-08-30 | Herman Adlercreutz | Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors |
AU2007227256B2 (en) * | 2006-03-20 | 2012-10-04 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
AU2007240613B2 (en) * | 2006-04-20 | 2013-11-28 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
US8747870B2 (en) | 2006-04-20 | 2014-06-10 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
WO2008008859A2 (en) * | 2006-07-11 | 2008-01-17 | University Of Utah Research Foundation | Macromolecules modified with electrophilic groups and methods of making and using thereof |
JP5290189B2 (ja) * | 2006-11-30 | 2013-09-18 | エンディース エルエルシー | 6−アルコキシアルキルエストラジオール誘導体およびその使用 |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US20080234243A1 (en) * | 2007-01-31 | 2008-09-25 | Lavallee Theresa M | Method of treating amyloidosis mediated diseases |
US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
WO2008137599A2 (en) * | 2007-05-01 | 2008-11-13 | Evestra, Inc. | 2-alkoxyestradiol analogs and pharmaceutical preparations |
CA2705152C (en) | 2007-11-09 | 2016-10-11 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
EP2633864A1 (en) | 2008-07-25 | 2013-09-04 | The Regents of the University of Colorado | Clip inhibitors and methods of modulating immune function |
US7901904B2 (en) * | 2008-10-16 | 2011-03-08 | Naxospharma S.R.L. | Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds |
WO2010132498A1 (en) * | 2009-05-11 | 2010-11-18 | Oxigene, Inc. | Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy |
MX361709B (es) | 2009-11-09 | 2018-12-07 | Allergan Inc | Composiciones y metodos para estimular el crecimiento del cabello. |
DK2616477T3 (en) | 2010-09-14 | 2017-02-20 | Endece Llc | 6-substituted demethyl estradiol derivatives as agonists of the type ER-BETA |
EP2649095B1 (en) | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
US20120225849A1 (en) * | 2011-03-01 | 2012-09-06 | The University Of Kansas | 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
JP6511401B2 (ja) | 2013-02-15 | 2019-05-15 | アラーガン、インコーポレイテッドAllergan,Incorporated | 持続型薬物送達インプラント |
US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
PL3040075T3 (pl) * | 2014-12-30 | 2018-03-30 | Curadis Gmbh | Steroidy c-19 do hamowania neowaskularyzacji |
US9907751B2 (en) * | 2016-03-10 | 2018-03-06 | RxOMEG Therapeutics LLC | Composition and method of use of colchicine oral liquid |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
WO2018145109A1 (en) | 2017-02-06 | 2018-08-09 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
US10226423B1 (en) | 2017-12-20 | 2019-03-12 | RxOMEG Therapeutics LLC | Colchicine drug-to-drug interactions |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2584271A (en) * | 1948-06-19 | 1952-02-05 | Searle & Co | Steroid derivatives and method for producing the same |
GB857080A (en) | 1956-05-29 | 1960-12-29 | Syntex Sa | Cyclopentanophenanthrene derivatives and process for the production thereof |
GB857081A (en) | 1956-05-29 | 1960-12-29 | Syntex Sa | Cyclopentanophenanthrene derivatives and process for the production thereof |
US3166577A (en) * | 1956-05-29 | 1965-01-19 | Syntex Corp | 1, 2-dimethyl estrogens and intermediates used in the production thereof |
US2846453A (en) * | 1957-05-28 | 1958-08-05 | Searle & Co | Alpha-ring-acylated estrone derivatives, and corresponding alcohols, their esters, and ethers |
JPS42928Y1 (ja) | 1964-07-25 | 1967-01-19 | ||
US3562260A (en) * | 1965-08-23 | 1971-02-09 | Ormonoterapia Richter Spa | 2-carbonyl-estratrienes and method of their preparation |
US3470218A (en) * | 1966-12-27 | 1969-09-30 | Allied Chem | New 2-substituted estrogenic steroids |
US3410879A (en) * | 1967-04-12 | 1968-11-12 | American Home Prod | Process for preparing gonahexaenes |
US3492321A (en) * | 1968-01-22 | 1970-01-27 | Syntex Corp | Cyclopropenyl estra, -1,3,5(10)-trienes |
US3496272A (en) * | 1968-01-23 | 1970-02-17 | American Home Prod | Ester of 3-(2-propynyloxy)-estradiol |
US3487155A (en) | 1968-02-19 | 1969-12-30 | Sandoz Ag | Substituted estradiol alkyl ethers |
DE2004516A1 (en) | 1969-03-05 | 1970-09-10 | VEB Jenapharm, Jena | Thermpentic steroidal sulphonate esters |
US3950437A (en) | 1972-12-25 | 1976-04-13 | Oxirane Chemical Co. | Method for manufacture of dihydric phenols |
GB1502635A (en) * | 1974-02-27 | 1978-03-01 | Schering Ag | Process for splitting steroid ethers |
JPS5265259A (en) | 1975-11-27 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of 16beta-alkylestradiol or its 17-esters |
NL7613248A (nl) * | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
US4172132A (en) * | 1977-07-26 | 1979-10-23 | Schering Corporation | 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor |
DE2757157C3 (de) | 1977-12-19 | 1980-10-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 16 a -alkylierten Steroiden |
FR2515188A1 (fr) * | 1981-10-27 | 1983-04-29 | Roussel Uclaf | Nouveaux derives du 3-amino-pregn-5-ene, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
FI830078L (fi) | 1982-01-15 | 1983-07-16 | Lilly Co Eli | Askorbinsyraetrar och liknande foereningar |
US5001116A (en) * | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4552758A (en) * | 1983-12-20 | 1985-11-12 | St. Jude Children's Research Hospital | Human use of avian-human reassortants as vaccines for influenza A virus |
US4522758A (en) * | 1983-12-22 | 1985-06-11 | Eli Lilly And Company | Method of preparing 2-fluoro-17β-estradiol |
EP0166937B1 (en) | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
US4634705A (en) * | 1984-06-06 | 1987-01-06 | Abbott Laboratories | Adrenergic amidines |
SU1240038A1 (ru) | 1984-11-23 | 1996-10-27 | Уральский политехнический институт им.С.М.Кирова | 3-оксиэстра-1,3,5-триен-17-гидразон, обладающий гормональной и противоопухолевой активностью |
EP0243449A1 (en) | 1985-10-18 | 1987-11-04 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
JPS62135472A (ja) | 1985-12-10 | 1987-06-18 | Yakult Honsha Co Ltd | 新規な1,2−ビス−3,5−ジオキソピペラジニルエタン誘導体 |
US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
JP2544136B2 (ja) | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ds4152を含有する血管新生抑制剤及び抗腫瘍剤 |
DE3625315A1 (de) | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
JP2517561B2 (ja) | 1986-10-03 | 1996-07-24 | 新技術事業団 | カテコ−ルエストロゲンのイムノアツセイキツド |
US5352664A (en) | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
DE3872234T2 (de) | 1987-04-16 | 1993-01-07 | Upjohn Co | Zyklische kohlenwasserstoffe mit aminoalkyl-seitenkette. |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
JPH01240038A (ja) | 1988-03-19 | 1989-09-25 | Fujitsu Ltd | ピーク値比較型タイミング再生方式 |
WO1990015816A1 (en) | 1989-06-16 | 1990-12-27 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
US4990538A (en) * | 1989-08-23 | 1991-02-05 | Harris Adrian L | Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
JPH03240726A (ja) | 1990-02-15 | 1991-10-28 | Fujisawa Pharmaceut Co Ltd | 化学療法効果増強剤 |
JPH0446120A (ja) | 1990-06-11 | 1992-02-17 | Kyowa Hakko Kogyo Co Ltd | 血管新生抑制剤 |
IT1247827B (it) | 1991-02-05 | 1995-01-02 | Erba Carlo Spa | Benzoil carbinolo e suoi esteri, utili come inibitori dell'angiogenesi |
WO1993003729A1 (en) * | 1991-08-12 | 1993-03-04 | Research Corporation Technologies, Inc. | N-substituted phenoxazines for treating multidrug resistant cancer cells |
US6011024A (en) * | 1991-08-28 | 2000-01-04 | Imperial College Of Science Technology & Medicine | Steroid sulphatase inhibitors |
CA2425849C (en) * | 1991-11-22 | 2007-02-27 | Alcon Laboratories, Inc. | Angiostatic steroids |
PL171920B1 (pl) | 1991-12-02 | 1997-06-30 | Cor Therapeutics Inc | Sposób wytwarzania nowego, hamujacego PDGF-R polipeptydy immunoglobulinowego PL |
GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
DE4235657A1 (de) * | 1992-10-22 | 1994-06-23 | Schering Ag | Verfahren zum Alkylieren von Östronderivaten |
EP0678296A1 (en) * | 1993-01-11 | 1995-10-25 | TSUMURA & CO. | Vascularization inhibitor and novel compound |
WO1994027635A1 (en) * | 1993-05-27 | 1994-12-08 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
US5643900A (en) * | 1993-07-02 | 1997-07-01 | Fotsis; Theodore | Method for treatment of pathological conditions associated with angiogenesis and preparation therefor |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6908910B2 (en) * | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
EP0758390B1 (en) * | 1994-04-26 | 2007-02-28 | The Children's Medical Center Corporation | Angiostatin and method of use for inhibition of angiogenesis |
US5837682A (en) * | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5861372A (en) * | 1996-02-22 | 1999-01-19 | The Children's Medical Center Corporation | Aggregate angiostatin and method of use |
US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US5854221A (en) * | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
EP0888310B1 (en) * | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
ATE281170T1 (de) * | 1996-05-09 | 2004-11-15 | Amrad Operations Pty Ltd | Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen |
US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
US5763432A (en) * | 1997-01-29 | 1998-06-09 | Sri International | Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use |
US6051726A (en) * | 1997-03-13 | 2000-04-18 | Pharm-Eco Laboratories, Inc. | Synthesis of 2-alkoxyestradiols |
US6136992A (en) * | 1997-03-13 | 2000-10-24 | The United States Of America As Represented By The Department Of Health And Human Services | 2-alkoxy estradiols and derivatives thereof |
CA2208916A1 (en) | 1997-07-03 | 1999-01-03 | Hyal Pharmaceutical Corporation | Promotion of wound healing utilizing steroids having reduced deterioroussystemic side effects typical of glucocorticoids, mineralocorticoids andsex steroids |
US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
AU1289899A (en) | 1997-10-31 | 1999-05-24 | Arch Development Corporation | Methods and compositions for regulation of 5-alpha reductase activity |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6046186A (en) * | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
JPH11209322A (ja) | 1998-01-27 | 1999-08-03 | Kao Corp | イソバニリルアルコール誘導体 |
WO2000007576A2 (en) | 1998-08-07 | 2000-02-17 | Endorecherche, Inc. | INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE |
ATE284682T1 (de) * | 1998-08-11 | 2005-01-15 | Entremed Inc | Verwendung von 2-methoxyestradiol als fungizide |
AU5687199A (en) | 1998-08-24 | 2000-03-14 | Global Vascular Concepts, Inc. | Use of anti-angiogenic agents for inhibiting vessel wall injury |
US6284789B1 (en) * | 1998-09-04 | 2001-09-04 | The Research Foundation Of State University Of New York | Formation and composition of new optically active compounds |
WO2000025780A1 (en) * | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
US6358940B1 (en) * | 1999-09-07 | 2002-03-19 | Rutgers, The State University | Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity |
-
1993
- 1993-08-06 US US08/102,767 patent/US5504074A/en not_active Expired - Lifetime
-
1994
- 1994-08-02 DE DE69434584T patent/DE69434584T2/de not_active Expired - Fee Related
- 1994-08-02 DK DK94924120T patent/DK0713393T3/da active
- 1994-08-02 ES ES05016659T patent/ES2315763T3/es not_active Expired - Lifetime
- 1994-08-02 JP JP7506502A patent/JPH09501433A/ja not_active Ceased
- 1994-08-02 EP EP05016659A patent/EP1640009B1/en not_active Expired - Lifetime
- 1994-08-02 AU AU74509/94A patent/AU7450994A/en not_active Abandoned
- 1994-08-02 ES ES94924120T patent/ES2255704T3/es not_active Expired - Lifetime
- 1994-08-02 DE DE69435151T patent/DE69435151D1/de not_active Expired - Fee Related
- 1994-08-02 DK DK05016659T patent/DK1640009T3/da active
- 1994-08-02 AT AT94924120T patent/ATE313327T1/de not_active IP Right Cessation
- 1994-08-02 WO PCT/US1994/008767 patent/WO1995004535A1/en active IP Right Grant
- 1994-08-02 EP EP94924120A patent/EP0713393B1/en not_active Expired - Lifetime
- 1994-08-02 AT AT05016659T patent/ATE411029T1/de not_active IP Right Cessation
- 1994-08-02 CA CA002168850A patent/CA2168850C/en not_active Expired - Fee Related
- 1994-08-02 PT PT05016659T patent/PT1640009E/pt unknown
- 1994-08-02 EP EP08002915A patent/EP1927359A3/en not_active Withdrawn
-
1995
- 1995-12-12 US US08/571,265 patent/US5661143A/en not_active Expired - Lifetime
-
1997
- 1997-04-25 US US08/838,699 patent/US5892069A/en not_active Expired - Fee Related
-
1998
- 1998-12-28 HK HK98115897A patent/HK1014504A1/xx not_active IP Right Cessation
-
1999
- 1999-02-02 US US09/243,158 patent/US6528676B1/en not_active Expired - Fee Related
-
2001
- 2001-02-12 US US09/780,650 patent/US7109187B2/en not_active Expired - Fee Related
-
2002
- 2002-09-25 US US10/255,652 patent/US20030055029A1/en not_active Abandoned
- 2002-10-25 US US10/280,831 patent/US7012070B2/en not_active Expired - Fee Related
-
2006
- 2006-04-12 US US11/402,386 patent/US7291610B2/en not_active Expired - Fee Related
- 2006-09-19 HK HK06110396.3A patent/HK1089387A1/xx not_active IP Right Cessation
-
2008
- 2008-02-22 JP JP2008041709A patent/JP2008120839A/ja active Pending
- 2008-02-22 JP JP2008041711A patent/JP2008120840A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09501433A (ja) | 抗−分裂剤としてのエストロゲン性化合物 | |
US7081477B2 (en) | Estrogenic compounds as anti-mitotic agents | |
KR100243537B1 (ko) | 에스트라-1,3,5(10)-트리엔 유도체를 함유한 약제학적 조성물 | |
US20020002294A1 (en) | Estrogenic compounds as antiangiogenic agents | |
JPH10503180A (ja) | エストラ−1,3,5(10)−トリエン誘導体、これらの製造方法及びこれら化合物を含有する製薬組成物 | |
RU2159774C2 (ru) | Производные сульфамата, способ их получения и фармацевтические составы | |
JP2002543114A (ja) | 抗腫瘍剤としてのエストロン誘導体の使用 | |
US20040214807A1 (en) | Estrogenic compounds as anti-mitotic agents | |
ES2286042T3 (es) | 18-nor-esteroides como estrogenos eficaces selectivamente. | |
EP0850647B1 (fr) | Application de composés stéroides substitués en ll pour la fabrication de médicaments ayant une activité estrogène dissociée | |
JP2010533152A (ja) | 選択的に活性なエストロゲンとしての8β−置換エストラトリエン | |
US20030195180A1 (en) | Estrogenic compounds as anti-mitotic agents | |
DE19954105A1 (de) | 18-Nor-Steroide als selektiv wirksame Estrogene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050520 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060825 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080207 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080128 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080417 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090317 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090323 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090420 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090423 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20101026 |